Pharmaceutical kits and uses thereof for treating colorectal cancer

Abstract

This disclosure in general describes a pharmaceutical kit for treating colorectal cancer; the pharmaceutical kit comprises (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide, and an anti-PD-1 or anti-PD-L1 antibody. Furthermore, this disclosure describes a method for treating colorectal cancer in a subject, comprising administering to the subject the aforementioned pharmaceutical kit, wherein the (E)-N-hydroxy-3-(1-(phenylsulfonyl)-indolin-5-yl)-acrylamide is given to the subject in a dosage ranging from about 10 μg/kg to 1 g/kg; and the anti-PD-1 or anti-PD-L1 antibody is administered to the subject at a dosage ranging from about 1 μg/kg to 100 mg/kg.

Dependencies are inferred from the claim text.